Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Gene Therapy Company Calls Off Diabetic Macular Edema Program

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.

Eye
Adverum is shifting the focus of its gene therapy from DME to wet AMD, but it faces a challenging path forward • Source: Shutterstock

Adverum Biotechnologies, Inc. is shifting its focus to wet age-related macular degeneration (AMD) after discontinuing development of its gene therapy, ADVM-022, in diabetic macular edema (DME) following a series of adverse events among patients with DME who received the therapy. Nevertheless, it faces a tough road ahead as the adverse events could invite scrutiny from physicians, patients and regulators despite not occurring in wet AMD, a disease area that is also highly competitive.

Redwood City, CA-based Adverum said 22 July that it will shut down its DME development program for ADVM-022, but it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D